Antithrombotic therapy in patients undergoing coronary angioplasty.
Popma
J J
JJ
Interventional Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. jjpopma@bics.bwh.harvard.edu
Weitz
J
J
Bittl
J A
JA
Ohman
E M
EM
Kuntz
R E
RE
Lansky
A J
AJ
King
S B
SB
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D003327:Coronary Disease / Q000628:therapy; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012008:Recurrence; D015607:Stents
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin; D001241:Aspirin; D000077284:Abciximab